Affiliation: Stanford University
- Warfarin prevails for stroke prevention in atrial fibrillation--even in octogenariansGregory W Albers
Lancet Neurol 6:844-6. 2007
- Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trialGregory W Albers
Stanford University Medical Center, Palo Alto, CA, USA Electronic address
Lancet Neurol 14:575-84. 2015..We aimed to assess the safety and efficacy of desmoteplase, a fibrin-dependent plasminogen activator, given between 3 h and 9 h after symptom onset in patients with occlusion or high-grade stenosis in major cerebral arteries...
- Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) studyGregory W Albers
Department of Neurology and Neurological Sciences and the Stanford Stroke Center, Stanford University Medical Center, Stanford, CA 94304, USA
Ann Neurol 60:508-17. 2006..To determine whether prespecified baseline magnetic resonance imaging (MRI) profiles can identify stroke patients who have a robust clinical response after early reperfusion when treated 3 to 6 hours after symptom onset...
- Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Gregory W Albers
Stanford University Medical Center, Stanford Stroke Center, 701 Welch Road, Palo Alto, CA 94304 1705, USA
Chest 133:630S-669S. 2008..5; range, 2.0 to 3.0) [Grade 1A]. In patients with venous sinus thrombosis, we recommend unfractionated heparin (Grade 1B) or low-molecular-weight heparin (Grade 1B) over no anticoagulant therapy during the acute phase...
- Intravenous alteplase for ischaemic strokeGregory W Albers
Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford University Medical Center, Stanford, CA 94305, USA
Lancet 369:249-50. 2007
- Can the ESPRIT results end the antiplatelet battle between neurologists and cardiologists?Gregory W Albers
Neurology and Neurological Sciences, Stanford University, 701 Welch Road 325, Stanford, CA 94305, USA
Nat Clin Pract Cardiovasc Med 4:118-9. 2007
- Yield of combined perfusion and diffusion MR imaging in hemispheric TIAM Mlynash
Department of Neurology and Neurological Sciences, Stanford Stroke Center, 701 Welch Road, Suite B325, Palo Alto, CA 94304, USA
Neurology 72:1127-33. 2009..Diffusion-weighted MRI (DWI) demonstrates acute ischemic lesions in approximately 30% of TIA patients; the yield of perfusion-weighted MRI (PWI) is unclear...
- Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapiesGregory W Albers
Stanford Stroke Center, 780 Welch Road, Suite 205, Palo Alto, CA 94304, USA
Stroke 42:2645-50. 2011....
- TIA triage in emergency department using acute MRI (TIA-TEAM): a feasibility and safety studyNirali Vora
Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA, USA
Int J Stroke 10:343-7. 2015..Positive diffusion weighted imaging (DWI) on MRI is associated with increased recurrent stroke risk in TIA patients. Acute MRI aids in TIA risk stratification and diagnosis...
- Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patientsJens Fiehler
Department of Neuroradiology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
Stroke 38:2738-44. 2007..Because of this concern, some centers withhold potentially beneficial thrombolytic therapy from these patients...
- Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE)Jean Marc Olivot
Department of Neurology and Neurological Sciences and the Stanford Stroke Center, Stanford University Medical Center, 701 Welch Road, Suite 325, Palo Alto, CA 94304, USA
Stroke 39:2257-63. 2008..The purpose of this study was to determine the relationships between ischemic lesion growth, recanalization, and clinical response in stroke patients with and without a perfusion/diffusion mismatch...
- Perfusion mapping with multiecho multishot parallel imaging EPIRexford D Newbould
Lucas MRS I Center, Department of Radiology, Stanford University, Stanford, California 94305 5488, USA
Magn Reson Med 58:70-81. 2007..The use of this method for DSC addresses the problem of signal saturation and T(1) contamination while it improves image quality, and is a logical step toward better quantitative MR PWI...
- Neurological picture. Acute strokes in the setting of a persistent primitive trigeminal arteryNeil E Schwartz
Stanford Stroke Center, Stanford University Medical Center, 701 Welch Road, Suite B325, Palo Alto, CA 94304 5749, USA
J Neurol Neurosurg Psychiatry 78:745. 2007
- Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute strokeMaarten G Lansberg
Stanford University, Stanford Stroke Center, Palo Alto, California 94304, USA
Stroke 38:2275-8. 2007..MRI-based variables have generally not been included in predictive models, and little is known about the influence of reperfusion on SICH risk...
- Transient isolated vertigo secondary to an acute stroke of the cerebellar nodulusNeil E Schwartz
Stanford Stroke Center, Stanford University Medical Center, 701 Welch Rd, Suite B325, Palo Alto, CA 94304 5749, USA
Arch Neurol 64:897-8. 2007
- Optimal definition for PWI/DWI mismatch in acute ischemic stroke patientsWataru Kakuda
Department of Rehabilitation Medicine, Jikei University School of Medicine, Minato ku, Tokyo, Japan
J Cereb Blood Flow Metab 28:887-91. 2008..Defining mismatch with a larger PWI/DWI ratio may provide greater power for detecting beneficial effects of reperfusion...
- Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?Neil E Schwartz
Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford University, 701 Welch Road, B325, Palo Alto, CA 94304, USA
Curr Neurol Neurosci Rep 8:29-34. 2008..The combination of aspirin and extended-release dipyridamole has demonstrated superiority over aspirin in two large secondary stroke prevention trials...
- Acute stroke imaging research roadmapMax Wintermark
University of California, San Francisco, Department of Radiology, Neuroradiology Section, 505 Parnassus Avenue, Box 0628, San Francisco, CA 94143 0628, USA
Stroke 39:1621-8. 2008..The present article summarizes these recommendations and examines practical steps to achieve them...
- Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE studyMichael P Marks
Department of Radiology, Neurosurgery, Stanford University Medical Center, Stanford, CA 94305 5105, USA
Radiology 249:614-23. 2008..To study magnetic resonance (MR) angiography findings in patients with acute stroke treated with intravenous tissue plasminogen activator (tPA) in relationship to perfusion- and diffusion-weighted imaging changes and clinical outcome...
- Aspirin and extended-release dipyridamole versus clopidogrel for recurrent strokeRalph L Sacco
Miller School of Medicine, University of Miami, Miami, USA
N Engl J Med 359:1238-51. 2008..Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel...
- The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusionMaarten G Lansberg
Stanford Stroke Center, 701 Welch Road, Suite B325, Palo Alto, CA 94304 9705, USA
Stroke 39:2491-6. 2008....
- Optimal outcome measures for detecting clinical benefits of early reperfusion: insights from the DEFUSE StudyWataru Kakuda
Department of Rehabilitation Medicine, Jikei University School of Medicine, Tokyo, Japan
J Stroke Cerebrovasc Dis 17:235-40. 2008..There is no consensus regarding which clinical outcome scales are the most sensitive indicators of early reperfusion in patients with acute stroke...
- Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillationJeanne S Teitelbaum
Department of Neurology, Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada
Can J Neurol Sci 35:160-5. 2008..We assessed any differential effect of warfarin versus ximelagatran on the risk and outcome of cardioembolic and noncardioembolic stroke...
- Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Daniel E Singer
Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
Chest 133:546S-592S. 2008..However, in patients without contraindications to anticoagulation, we suggest beginning IV heparin or LMWH at presentation (Grade 2C)...
- Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jack Hirsh
Hamilton Civic Hospitals, Hamilton, Ontario, Canada
Chest 133:110S-112S. 2008....
- Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jack Hirsh
Hamilton Civic Hospitals, Hamilton, Ontario, Canada
Chest 133:71S-109S. 2008
- Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factorsMaarten G Lansberg
Stanford University, Stanford Stroke Center, Palo Alto, CA 94304, USA
Cerebrovasc Dis 24:1-10. 2007....
- Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSEMaarten G Lansberg
Stanford Stroke Center, Stanford University Medical Center, Palo Alto, CA 94304, USA
Stroke 38:1826-30. 2007..The clinical-diffusion mismatch (CDM) model is an alternative method that is technically less challenging because it does not require perfusion-weighted imaging. This study is an evaluation of these 2 models in the DEFUSE dataset...
- Clinical multishot DW-EPI through parallel imaging with considerations of susceptibility, motion, and noiseStefan Skare
Lucas MRS I Center, Department of Radiology, Stanford University, California 94305, USA
Magn Reson Med 57:881-90. 2007..The image quality improvements without SNR efficiency loss, together with motion tolerance, make the GRAPPA-driven DW-EPI sequence clinically attractive...
- Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trialGregory W Albers
Stanford Stroke Center, Palo Alto, Calif, USA
JAMA 293:690-8. 2005..In patients with nonvalvular atrial fibrillation, warfarin prevents ischemic stroke, but dose adjustment, coagulation monitoring, and bleeding limit its use...
- Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trialsGregory W Albers
Stanford Stroke Center, Palo Alto, California, USA
Am J Manag Care 10:S462-9; discussion S469-73. 2004..This oral direct thrombin inhibitor is a potentially promising treatment option for the prevention of thromboembolism...
- Diffusion-weighted MR imaging in acute ischemia: value of apparent diffusion coefficient and signal intensity thresholds in predicting tissue at risk and final infarct sizeDong Gyu Na
Department of Radiology, Stanford University Medical Center, Stanford, CA 94305 5105, USA
AJNR Am J Neuroradiol 25:1331-6. 2004..This study was performed to determine whether pixel-based apparent diffusion coefficient (ADC) and signal intensity ratio are helpful diffusion-weighted (DW) imaging metrics to predict tissue at risk for infarction...
- Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyGregory W Albers
Stanford University Medical Center, Stanford Stroke Center, 701 Welch Rd, Building B, Suite 325, Palo Alto, CA 94304 1705, USA
Chest 126:483S-512S. 2004..5; range, 2.0 to 3.0) [Grade 1A]. In patients with venous sinus thrombosis, we recommend unfractionated heparin (Grade 1B) or low molecular weight heparin (Grade 1B) over no anticoagulant therapy during the acute phase...
- Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyDaniel E Singer
Clinical Epidemiology Unit, S50 9, Massachusetts General Hospital, Boston, MA 02114, USA
Chest 126:429S-456S. 2004..However, in patients without contraindications to anticoagulation, we suggest beginning IV heparin or low molecular weight heparin at presentation (Grade 2C)...
- A review of published TIA treatment recommendationsGregory W Albers
Stanford Stroke Center, Stanford University, Palo Alto, CA, USA
Neurology 62:S26-8. 2004
- Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillationStanley G Rockson
Division of Cardiovascular Medicine, Falk Cardiovascular Research Center, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA
J Am Coll Cardiol 43:929-35. 2004....
- Influence of arterial input function on hypoperfusion volumes measured with perfusion-weighted imagingVincent N Thijs
Department of Neurology, UZ Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
Stroke 35:94-8. 2004..We studied the effect of varying the location of measurement of AIF on the volume of hypoperfusion. We compared the volumes of hypoperfusion obtained with different AIFs with the final ischemic lesion volume...
- Patient safety in trials of therapy for acute ischemic strokeLarry B Goldstein
JAMA 287:987. 2002
- Oral antiplatelet therapyRichard A Bernstein
JAMA 293:793-4; author reply 794-5. 2005
- Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtableMarc Fisher
UMass Memorial Healthcare Center, 119 Belmont St, Worcester, MA 01605, USA
Stroke 36:1808-13. 2005..A fourth (STAIR-IV) was held to discuss relevant issues related to acute stroke drug development and regulatory approval...
- ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic StrokeGregory W Albers
Stanford University School of Medicine, Stanford, Calif, USA
Stroke 33:493-5. 2002..Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients...
- The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparisonDavid G Sherman
Department of Medicine Neurology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
Lancet 369:1347-55. 2007..We aimed to compare the efficacy and safety of enoxaparin with that of unfractionated heparin for patients with stroke...
- Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and VHarvey D White
Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1030, New Zealand
Arch Intern Med 167:239-45. 2007..Target INRs are frequently not achieved, and the risk of death, bleeding, myocardial infarction (MI), and stroke or systemic embolism event (SEE) may be related to INR control...
- Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trialsPaul T Akins
Mercy Stroke Center, Sacramento, CA, USA
Stroke 38:874-80. 2007..Patients with nonvalvular atrial fibrillation and prior stroke or transient ischemic attack (TIA) are at high risk for recurrent stroke. We investigated whether ximelagatran was noninferior to warfarin in patients with prior stroke or TIA...
- Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imagingOliver C Singer
Klinik fur Neurologie, Universitatsklinik, Johann Wolfgang von Goethe Universität, Frankfurt, Germany
Ann Neurol 63:52-60. 2008..Here, we investigated the relation between pretreatment DWI lesion size and the risk for sICH after thrombolysis...
- Identifying systematic errors in quantitative dynamic-susceptibility contrast perfusion imaging by high-resolution multi-echo parallel EPIThies H Jochimsen
Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr 1a, D 04103 Leipzig, Germany
NMR Biomed 20:429-38. 2007..Therefore, DSC-MRI requires knowledge of the exact dependency of transverse relaxation rate upon tracer concentration in order to calculate truly quantitative perfusion maps...
- Acute cerebrovascular syndrome: time for new terminology for acute brain ischemiaGregory W Albers
Nat Clin Pract Cardiovasc Med 3:521. 2006
- Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onsetAnthony J Furlan
Department of Neurology, The Cleveland Clinic, Cleveland, OH 44195, USA
Stroke 37:1227-31. 2006..This study evaluated safety and efficacy of intravenous (IV) desmoteplase in patients with perfusion/diffusion mismatch on MRI 3 to 9 hours after onset of acute ischemic stroke...
- Mechanical thrombectomy following intravenous thrombolysis in the treatment of acute strokeMaarten G Lansberg
Department of Neurology, Stanford University Medical Center, Stanford, Calif 94305, USA
Arch Neurol 62:1763-5. 2005..Treatment with intravenous thrombolytics followed by mechanical thrombectomy is a novel approach that may increase recanalization rates without compromising time to initiation of treatment...
- Safety and tolerability of arundic acid in acute ischemic strokeL Creed Pettigrew
Stroke Program, Sanders Brown Center on Aging, and Department of Neurology, 101 Sanders Brown Building, University of Kentucky Medical Center, Lexington, KY 40536 0230, USA
J Neurol Sci 251:50-6. 2006..023 vs. placebo), 7 (p=0.002), 10 (p=0.003), and 40 (p=0.018). A dose of 8 mg/kg/h AA produced a favorable trend in reduction of NIHSS that should be confirmed in a future clinical trial...
- Trials and tribulations of noninferiority: the ximelagatran experienceGregory W Albers
J Am Coll Cardiol 48:1058; author reply 1059. 2006
- Optimizing oral anticoagulation in managed careJ Jaime Caro
Caro Research, Concord, Massachusetts, USA
Am J Manag Care 10:S474-7. 2004
- Telmisartan to prevent recurrent stroke and cardiovascular eventsSalim Yusuf
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
N Engl J Med 359:1225-37. 2008..We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke...
- Intracranial angioplasty without stenting for symptomatic atherosclerotic stenosis: long-term follow-upMichael P Marks
Department of Radiology, Stanford University Medical Center, Stanford, CA 94305, USA
AJNR Am J Neuroradiol 26:525-30. 2005..This study was undertaken to assess the efficacy and long-term clinical outcome of angioplasty without stent placement for patients with symptomatic intracranial stenosis...
- Clinical and radiological correlates of reduced cerebral blood flow measured using magnetic resonance imagingVincent N Thijs
Department of Neurology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Herestraat 49, 3000 Leuven, Belgium
Arch Neurol 59:233-8. 2002..Reduced apparent diffusion coefficient (ADC) values of brain tissue are associated with reductions in regional CBF in animal stroke models...
- Acute stroke imaging research roadmapMax Wintermark
Department of Radiology, University of California, San Francisco, CA 94143 0628, USA
AJNR Am J Neuroradiol 29:e23-30. 2008..The present article summarizes these recommendations and examines practical steps to achieve them...
- New MRI techniques for cerebrovascular diseasesGregory Albers; Fiscal Year: 2008..This K24 research program will expand Dr. Albers' skills as a clinical investigator and allow him to become a more effective mentor. [unreadable] [unreadable]..
- Diffusion weighted imaging Evaluation For Understanding Stroke Evolution2:DEFUSE Gregory W Albers; Fiscal Year: 2010..These findings will eventually lead to effective therapies for a large population of stroke patients who are currently ineligible for treatment and substantially reduce stroke-related disability. ..